Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XF0S | ISIN: US00972D1054 | Ticker-Symbol: AX9
Tradegate
31.03.25
15:35 Uhr
1,720 Euro
-0,048
-2,71 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AKEBIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
AKEBIA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,7581,80016:31
1,7581,77016:29

Aktuelle News zur AKEBIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPiper Sandler maintains Akebia stock with $6 price target2
AKEBIA Aktie jetzt für 0€ handeln
DiAkebia Therapeutics, Inc.: Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 20252
21.03.Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering3
21.03.Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?4
20.03.Akebia Therapeutics Announces $50 Mln Public Offering Of Common Stock1
20.03.Akebia Therapeutics, Inc. - 8-K, Current Report3
20.03.Pre-market Movers: SAG Holdings, OptiNose, ProAssurance, Akebia Therapeutics, Aditx Therapeutics392BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Sag Holdings Inc (SAG) is up over 67% at $1.13. OptiNose...
► Artikel lesen
20.03.Akebia Therapeutics, Inc.: Akebia Therapeutics Announces Pricing of Public Offering of Common Stock8
19.03.Akebia Therapeutics, Inc.: Akebia Therapeutics Announces Proposed Public Offering of Common Stock5
15.03.Piper Sandler Forecasts Strong Price Appreciation for Akebia Therapeutics (NASDAQ:AKBA) Stock4
14.03.Piper Sandler raises Akebia stock target to $6 on Vafseo launch10
14.03.Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2024 Earnings Call Transcript4
13.03.Amid Vafseo's US launch, Akebia plots phase 3 study to grow CKD anemia med's reach3
13.03.Akebia slumps after Q4 earnings miss12
13.03.Akebia Therapeutics, Inc. Q4 Earnings Summary4
13.03.Akebia Therapeutics, Inc. - 10-K, Annual Report-
13.03.Akebia Therapeutics, Inc. - 8-K, Current Report1
13.03.Akebia GAAP EPS of -$0.10 misses by $0.02, revenue of $46.49M beats by $9.13M3
12.03.Akebia Q4 2024 Earnings Preview3
06.03.Akebia Therapeutics, Inc.: Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights3
Seite:  Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1